CoChat

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial

Open access

Abstract

Background In the SURPASS-4 trial, the dual GIP and GLP-1 receptor agonist tirzepatide reduced HbA 1c concentrations, bodyweight, and blood pressure more than titrated daily insulin glargine in people with type 2 diabetes inadequately controlled on oral diabetes treatments and with high cardiovascular risk. We aimed to compare the effects of tirzepatide and insulin glargine on kidney parameters and outcomes in people with type 2 diabetes.Methods We did a post-hoc analysis of data from SURPASS-4, a randomised, open-label, parallel-group, phase 3 study at 187 sites (including private practice, research institutes, and hospitals) in 14 countries. Eligible participants were adults (age ≥18 years), with type 2 diabetes treated with any combination of metformin, sulfonylurea, or SGLT2 inhibitor, and with baseline HbA 1c of 7·5-10·5% (58-91 mmol/mol), BMI of 25 kg/m 2 or greater, and established cardiovascular disease or a high risk of cardiovascular events. Randomisation via an interactive web-response system was 1:1:1:3 to a once-weekly subcutaneous injection of tirzepatide (5 mg, 10 mg, or 15 mg) or a once-daily subcutaneous injection of titrated insulin glargine (100 U/mL). The study included up to 104 weeks of treatment, with a median treatment duration of 85 weeks. We compared the rates of estimated glomerular filtration rate (eGFR) decline and the urine albumin-creatinine ratio (UACR) between the combined tirzepatide groups and the insulin glargine group in the modified intention-to-treat population. The kidney composite outcome was time to first occurrence of eGFR decline of at least 40% from baseline, end-stage kidney disease, death owing to kidney failure, or new-onset macroalbuminuria. This study is registered with ClinicalTrials.gov, NCT03730662.Findings Between Nov 20, 2018, and Dec 30, 2019, we screened 3045 people, of whom 1043 (34%) were ineligible, and 2002 (66%) were randomly assigned to a study drug (997 to tirzepatide and 1005 to insulin glargine). 1995 (>99%) of 2002 received at least one dose of tirzepatide (n=995) or insulin glargine (n=1000). At baseline, participants had a mean eGFR of 81·3 (SD 21·11) mL/min per 1·73 m 2 and a median UACR of 15·0 mg/g (IQR 5·0-55·8). The mean rate of eGFR decline was -1·4 (SE 0·2) mL/min per 1·73 m 2 per year in the combined tirzepatide groups and -3·6 (0·2) mL/min per 1·73 m 2 per year in the insulin group (between-group difference 2·2 [95% CI 1·6 to 2·8]). Compared with insulin glargine, the reduction in the annual rate of eGFR decline induced by tirzepatide was more pronounced in participants with eGFR less than 60 mL/min per 1·73 m 2 than in those with eGFR 60 mL/min per 1·73 m 2 or higher (between-group difference 3·7 [95% CI 2·4 to 5·1]). UACR increased from baseline to follow-up with insulin glargine (36·9% [95% CI 26·0 to 48·7]) but not with tirzepatide (-6·8% [-14·1 to 1·1]; between-group difference -31·9% [-37·7 to -25·7]). Participants who received tirzepatide showed a significantly lower occurrence of the composite kidney endpoint compared with those who received insulin glargine (hazard ratio 0·58 [95% CI 0·43 to 0·80]).Interpretation Our analysis suggests that in people with type 2 diabetes and high cardiovascular risk, tirzepatide slowed the rate of eGFR decline and reduced UACR in clinically meaningful ways compared with insulin glargine.Funding Eli Lilly and Company.

Overview

CoChat Summary

TL;DR

In a post-hoc analysis of SURPASS-4, tirzepatide slowed the annual rate of eGFR decline and reduced UACR compared with titrated insulin glargine in adults with type 2 diabetes and high cardiovascular risk. Tirzepatide also reduced the composite kidney outcome by 42% (HR 0·58).

Key findings

  • Mean eGFR decline was –1·4 (SE 0·2) mL/min per 1·73 m² per year with tirzepatide versus –3·6 (0·2) with insulin glargine; between-group difference 2·2 (95% CI 1·6 to 2·8).
  • The benefit was larger in participants with baseline eGFR <60 mL/min per 1·73 m² (between-group difference 3·7 [95% CI 2·4 to 5·1]).
  • UACR rose with insulin glargine (36·9% [95% CI 26·0 to 48·7]) but not with tirzepatide (–6·8% [–14·1 to 1·1]); between-group difference –31·9% (–37·7 to –25·7).
  • Composite kidney endpoint (≥40% eGFR decline, end-stage kidney disease, kidney-failure death, or new-onset macroalbuminuria) occurred less often with tirzepatide: HR 0·58 (95% CI 0·43 to 0·80).

Methods

  • Post-hoc analysis of SURPASS-4, a randomised, open-label, parallel-group phase 3 trial at 187 sites in 14 countries; randomisation 1:1:1:3 to once-weekly tirzepatide (5, 10, or 15 mg) or once-daily titrated insulin glargine (100 U/mL), up to 104 weeks (median treatment 85 weeks).
  • Participants: adults (≥18 years) with type 2 diabetes on metformin, sulfonylurea, or SGLT2 inhibitor combinations, baseline HbA1c 7·5–10·5%, BMI ≥25 kg/m², and established or high-risk cardiovascular disease; 2002 randomised (997 tirzepatide, 1005 insulin glargine), 1995 received ≥1 dose.
  • Analysis compared eGFR decline rate and UACR between combined tirzepatide groups and insulin glargine in the modified intention-to-treat population; baseline mean eGFR 81·3 (SD 21·11) mL/min per 1·73 m², median UACR 15·0 mg/g (IQR 5·0–55·8).

Limitations

  • The paper describes this as a post-hoc analysis; no further limitations are stated in the provided text.
  • Evident from the text: the trial was open-label, and the kidney outcomes were not the primary endpoint of SURPASS-4; the provided text is the abstract only, so detailed subgroup and safety limitations are not available.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(22)00243-1

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 0 Not valid · 0 Not checked · 8 Own results and interpretations

  • The quote only partly states this claim. 1
  • It may state two separate claims as one. 4
  • Probably not a substantial claim. 2

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 44 references

Cited by

See all 306

Metadata

Authors
Heerspink, H. J. L., Sattar, N., Pavo, I., Haupt, A., Duffin, K. L., Yang, Z., Wiese, R. J., Tuttle, K. R., & Cherney, D. Z. I.
Affiliations
University Health Network (CA)
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2022-11
Volume
10
Issue
11
Pages
774-785
ISSN
2213-8587 (ISSN-L)
OpenAlex
W4296578151
Cited by
306
References
44
Citations by year
2026: 64 · 2025: 92 · 2024: 85 · 2023: 60 · 2022: 5
FWCI
44.81
Type
journal article
Language
en
Open access
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
tirzepatide, insulin glargine, type 2 diabetes, renal outcomes, estimated glomerular filtration rate decline, albumin-creatinine ratio, macroalbuminuria, end-stage renal disease, cardiovascular risk, GIP/GLP-1 receptor agonist, glycemic control, renal safety, weight gain, blood pressure
MeSH terms
Insulin Glargine, Tirzepatide, Adolescent, Adult, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Kidney, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. https://app.cochat.ai/papers/10.1016/s2213-8587(22)00243-1
The paper
Heerspink, H. J. L., Sattar, N., Pavo, I., Haupt, A., Duffin, K. L., Yang, Z., Wiese, R. J., Tuttle, K. R., & Cherney, D. Z. I. (2022). Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(22)00243-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.